Osiris Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 24,308 7,849 1,263 43,204
Cost of Revenue 6,656 2,551 531 62
Gross Profit 17,652 5,298 732 43,142
Operating Expenses
Research and Development 4,952 5,501 4,340 23,501
Sales, General and Admin. 15,533 5,630 7,169 6,450
Non-Recurring Items - - - -
Other - - - -
Operating Income (2,833) (5,833) (10,777) 13,191
Income From Continuing Operations
Add'l Income/Expense Items 414 49 100 175
Earnings Before Interest and Tax (2,419) (5,784) (10,677) 13,366
Interest Expense - - - -
Earnings Before Tax (2,419) (5,784) (10,677) 13,366
Income Tax (1,326) (37) (775) 241
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (1,093) (5,747) (9,902) 13,125
Non Recurring Events
Discontinued Operations 42,731 (5,318) 24,794 -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 41,638 (11,065) 14,892 13,125
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 41,638 (11,065) 14,892 13,125